Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Multiple sclerosis (MS) is a chronic degenerative disease of the brain and spinal cord, typically affecting young adults. Several disease-modifying drugs (DMD) including interferon β (IFN-β) 1a and 1b, glatiramer acetate (GA), natalizumab, mitoxantrone and fingolimod are licensed worldwide to reduce the frequency of clinical attacks with the hope of slowing disability progression. Women with MS are typically advised to discontinue DMD treatment before conceiving to minimize the risk of fetal harm, nonetheless, prenatal DMD exposure still occurs, in part because approximately 50% of pregnancies are unplanned. This study sought to ascertain whether there was a relationship between MS and the likelihood of unfavorable pregnancy and perinatal outcomes in women with MS. The impact of exposure to disease-modifying medication (DMT) in female MS patients was also studied. This is a Retrospective Cohort Study, It’s conducted from 2 year at Department of Neurology, Super Specialty Hospital, Govt. Medical College Jammu, Jammu and Kashmir, India, 180016. Pregnant women diagnosed with MS who were part of a population-based cohort. 200 patients were included in this study. We observed that, more number of patients had Cohabitation with partner in Without MS compared to Not Exposed to DMT, With MS and Exposed to DMT but this was not statistically significant. While maternal MS was associated with a small increased risk of few adverse pregnancy and neonatal outcomes, DMT exposure close to pregnancy was not associated with major adverse out- comes.
How to cite this article:
Sunny Raina, Bharti Sharma and Hardeep Kumar. Multiple Sclerosis in Pregnancy and Disease-modifying Drugs and Pregnancy Outcomes: A Population-Based Cohort Study.
DOI: https://doi.org/10.36478/10.59218/makrjms.2024.2.18.587.592
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2024.2.18.587.592